Use of steady-state oxygen gradients to modulate animal cell functions

• US 20060258000A1
• Filed: 02/26/2004
• Published: 11/16/2006
• Est. Priority Date: 02/26/2003
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Allen, Jared Whiting, Bhatia, Sangeeta N.
• Application Number:
  US10/547,057
• Publication Number:
  US 20060258000A1
• Time in Patent Office: Days
• US Class Current: 435/325
• CPC Class Codes: C12M 41/34 of gas

Abstract

The disclosure provides a bioreactor that allows steady-state oxygen gradients to be imposed upon in vitro culture systems. The bioreactor system of the disclosure has been applied to liver zonation and have shown that physiological oxygen gradients contribute to heterogeneity of tissue cultures in vitro.

Claims

1. A method comprising:

controlling an oxygen gradient across a population of cells in one or more bioreactors to modify a tissue morphology, function, and/or gene expression.

2. The method of claim 1, wherein the population of cells are substantially homogenous.

3. The method of claim 1, wherein the population of cells comprise two or more cell types.

4. The method of claim 3, wherein the two or more cell types comprise stromal cells and a cell type selected from the group consisting of hepatocytes, pancreatic cells, endothelial cells, epithelial cells, cancer cells, muscle cells, and kidney cells.

5. The method of claim 1, wherein the population of cells are selected from the group consisting of hepatocytes, pancreatic cells, endothelial cells, epithelial cells, cancer cells, muscle cells, kidney cells, and stromal cells.

6. The method of claim 1, wherein the population of cells comprises hepatocytes.

7. The method of claim 1, wherein the population of cells comprises stromal cells.

8. The method of claim 1, wherein the population of cells comprises a co-culture of stromal cells and hepatocytes.

9. The method of claim 8, wherein the co culture of stromal cells and hepatocytes are in a micropattern formation.

10. The method of claim 1, wherein the one or more bioreactors comprise:

a pump,

a gas exchange device,

at least one culture device comprising,

at least one housing;

at least one substrate,

at least one tissue binding surface on each of the at least one substrate,

wherein the housing comprises at least one wall, an inlet port and an outlet port, wherein the housing fluidly seals the tissue binding surface to provide a flow space in fluid communication with the inlet and outlet ports,

a gas sensor, and

a fluid reservoir,

wherein the pump, the gas exchange device, the culture device, the gas sensor and the fluid reservoir are in fluid communication, such that a fluid is pumped from the fluid reservoir through (i) the gas exchanger, (ii) the culture device, (iii) the gas sensor and returned to the fluid reservoir using the pump and wherein the population of cells is cultured on the tissue binding surface of the substrate and wherein the gas concentration is modulated by the gas exchange device and sensed by the gas sensor.

11. The method of claim 10, wherein the bioreactor further comprises a bubble trap between the gas exchange device and the culture device.

12. The method of claim 10, wherein the gas exchange device modifies the O₂ content of the fluid.

13. The method of claim 12, wherein the O₂ content is higher proximal to the inlet port of the culture device and decreases further distal from the inlet port.

14. The method of claim 10, wherein the gas exchange device comprises a gas sensor.

15. The method of claim 10, wherein the fluid is growth medium.

16. The method of claim 10, wherein the pump is a peristaltic pump.

17. The method of claim 10, wherein the pump is a syringe pump.

18. The method of claim 10, wherein the substrate is biocompatible.

19. The method of claim 18, wherein the tissue binding surface of the substrate comprises a material selected from the group consisting of polyamides;

polyesters;

polystyrene;

polypropylene;

polyacrylates;

polyvinyl compounds;

polycarbonate (PVC);

polytetrafluoroethylene (PTFE);

nitrocellulose;

cotton;

polyglycolic acid (PGA);

cat gut sutures;

cellulose;

dextran;

gelatin; and

glass.

20. The method of claim 18, wherein the substrate is modified to promote cell adhesion.

21. A bioreactor comprising:

at least one housing having an inlet port and an outlet port;

at least one substrate disposed in the at least one housing;

at least one tissue binding surface on each of the at least one substrate, the housing and tissue binding surface defining a flow space along the tissue binding surface;

a pump in fluid communication with the inlet port and the outlet port of the housing;

a gas exchange device disposed between the pump and the inlet port;

a fluid reservoir in fluid communication with the pump; and

a gas sensor disposed between the outlet port and the fluid reservoir,

wherein the pump, the gas exchange device, the flow space, the gas sensor and the fluid reservoir are in fluid communication, such that a fluid is pumped from the fluid reservoir through (i) the gas exchanger, (ii) the flow space, (iii) the gas sensor and returned to the fluid reservoir using the pump and wherein the gas concentration is modulated by the gas exchange device and sensed by the gas sensor.

22. The bioreactor of claim 21, further comprising a tissue disposed on the tissue binding surface.

23. The bioreactor of claim 22, wherein the tissue comprises parenchymal cells.

24. The bioreactor of claim 22, wherein the tissue comprises stromal cells.

25. The bioreactor of claim 23, wherein the tissue further comprises stromal cells.

26. The bioreactor of claim 23, wherein the parenchymal cells are hepatocyte cells.

27. The bioreactor of claim 25, wherein the parenchymal cells are hepatocyte cells.

28. The bioreactor of claim 21, wherein the substrate is substantially planar.

29. The bioreactor of claim 21, wherein the substrate is concave or convex.

30. The bioreactor of claim 21, wherein the at least one substrate comprises a plurality of substrates.

31. The bioreactor of claim 21, wherein the bioreactor further comprises a bubble trap between the gas exchange device and the inlet port.

32. The bioreactor of claim 21, wherein the gas exchange device modifies the O₂ content of the fluid.

33. The bioreactor of claim 32, wherein the O₂ content is higher proximal to the inlet port of the housing and decreases further distal from the inlet port.

34. The bioreactor of claim 21, wherein the gas exchange device comprises a gas sensor.

35. The bioreactor of claim 21, wherein the fluid is growth medium.

36. The bioreactor of claim 21, wherein the pump is a peristaltic pump.

37. The bioreactor of claim 21, wherein the pump is a syringe pump.

38. The bioreactor of claim 21, wherein the substrate is biocompatible.

39. The bioreactor of claim 21, wherein the tissue binding surface of the substrate comprises a material selected from the group consisting of polyamides;

polyesters;

polystyrene;

polypropylene;

polyacrylates;

polyvinyl compounds;

polycarbonate (PVC);

polytetrafluoroethylene (PTFE);

nitrocellulose;

cotton;

polyglycolic acid (PGA);

cat gut sutures;

cellulose;

dextran;

gelatin; and

glass.

40. The bioreactor of claim 21, wherein the substrate is modified to promote cell adhesion.

41. The bioreactor of claim 21, comprising one substrate and a plurality of tissue binding surface on the at least one substrate.

42. A method of producing a tissue, comprising:

seeding a population of cells on a substrate in a bioreactor system;

controlling an oxygen gradient across the population of cells in one or more bioreactors;

culturing the cells under conditions and for a sufficient period of time to generate a tissue.

43. The method of claim 42, wherein the population of cells are substantially homogenous.

44. The method of claim 42, wherein the population of cells comprise two or more cell types.

45. The method of claim 44, wherein the two or more cell types comprise stromal cells and a cell type selected from the group consisting of hepatocytes, pancreatic cells, endothelial cells, epithelial cells, cancer cells, muscle cells, and kidney cells.

46. The method of claim 42, wherein the population of cells are selected from the group consisting of hepatocytes, pancreatic cells, endothelial cells, epithelial cells, cancer cells, muscle cells, kidney cells, and stromal cells.

47. The method of claim 42, wherein the population of cells comprises hepatocytes.

48. The method of claim 42, wherein the population of cells comprises stromal cells.

49. The method of claim 42, wherein the population of cells comprises a co-culture of stromal cells and hepatocytes.

50. The method of claim 49, wherein the co-culture of stromal cells and hepatocytes are in a micropattern formation.

51. The method of claim 42, wherein the bioreactor comprises:

a pump,

a gas exchange device,

at least one culture device comprising,

at least one housing;

at least one substrate,

at least one tissue binding surface on each of the at least one substrate,

wherein the housing comprises at least one wall, an inlet port and an outlet port, wherein the housing fluidly seals the tissue binding surface to provide a flow space in fluid communication with the inlet and outlet ports,

a gas sensor, and

a fluid reservoir,

wherein the pump, the gas exchange device, the culture device, the gas sensor and the fluid reservoir are in fluid communication, such that a fluid is pumped from the fluid reservoir through (i) the gas exchanger, (ii) the culture device, (iii) the gas sensor and returned to the fluid reservoir using the pump, wherein the population of cells is cultured on the tissue binding surface of the substrate and wherein the gas concentration is modulated by the gas exchange device and sensed by the gas sensor.

52. The method of claim 51, wherein the bioreactor further comprises a bubble trap between the gas exchange device and the culture device.

53. The method of claim 51, wherein the gas exchange device modifies the O₂ content of the fluid.

54. The method of claim 53, wherein the O₂ content is higher proximal to the inlet port of the culture device and decreases further distal from the inlet port.

55. The method of claim 51, wherein the gas exchange device comprises a gas sensor.

56. The method of claim 51, wherein the fluid is growth medium.

57. The method of claim 51, wherein the pump is a peristaltic pump.

58. The method of claim 51, wherein the pump is a syringe pump.

59. The method of claim 51, wherein the substrate is biocompatible.

60. The method of claim 59, wherein the tissue binding surface of the substrate comprises a material selected from the group consisting of polyamides;

polyesters;

polystyrene;

polypropylene;

polyacrylates;

polyvinyl compounds;

polycarbonate (PVC);

polytetrafluoroethylene (PTFE);

nitrocellulose;

cotton;

polyglycolic acid (PGA);

cat gut sutures;

cellulose;

dextran;

gelatin; and

glass.

61. The method of claim 59, wherein the substrate is modified to promote cell adhesion.

62. A tissue produced by the method of claim 42.

63. An assay system comprising:

contacting a tissue produced by the method of claim 42 with a test agent and measuring an activity selected from gene expression, cell function, metabolic activity, morphology, and a combination thereof, of the tissue.

64. The assay system of claim 63, wherein the test agent is selected from a protein, a peptide, a polypeptide, an antibody, a peptidomimetic, a small molecule, an oligonucleotide, and a polynucleotide.

65. The assay system of claim 63, wherein the test agent is a cytotoxic agent.

66. The assay system of claim 63, wherein the test agent is a pharmaceutical agent.

67. The assay system of claim 63, wherein the test agent is a xenobiotic.

68. The assay system of claim 67, wherein the xenobiotic is selected from the group consisting of an environmental toxins, chemical/biological warfare agents, natural compounds such as holistic therapies and nutraceuticals.

69. The assay system of claim 63, wherein the activity is adsorption, distributions, metabolism, excretion, and toxicology (ADMET) of the test agent.

70. The assay system of claim 63, wherein the metabolic activity is protein production.

71. The assay system of claim 63, wherein the metabolic activity is enzyme bioproduct formation.